search
Back to results

Liposomal Vincristine Plus Dexamethasone in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

Primary Purpose

Acute Lymphoblastic Leukemia

Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Vincristine Sulfate Liposomes Injection
Dexamethasone
Sponsored by
Acrotech Biopharma Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Acute Lymphoblastic Leukemia

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Previously treated, relapsed or refractory ALL (including lymphoblastic lymphoma and Burkitt's subtypes) with measurable disease. Performance status ≤3 (ECOG). All ages are eligible. Those aged 12 years or older may be counted towards the MTD in the Phase I portion of the trial. Pediatric patients are eligible, but must be treated at a dose level previously tested in an adult (one full course). Adequate liver function (bilirubin ≤2 x upper limit normal), and renal function (creatinine ≤2 x upper limit normal). Negative pregnancy test in females of childbearing potential. Patients with prior history of stem cell transplant are eligible if they meet all other eligibility requirements. Exclusion Criteria: Active serious infection not controlled by oral or intravenous antibiotics. Treatment with any investigational agents or chemotherapy agents in the last 21 days before study entry, unless full recovery from side effects has occurred or the patient has rapidly progressive disease judged to be life threatening by the Investigator. Concurrent treatment with other anti-cancer agents other than dexamethasone. Known CNS leukemia or lymphoma requiring intrathecal or craniospinal radiation therapy or with CNS neuropathy limiting evaluation of study drug. Patients with controlled CNS disease (no progression signs or symptoms at the time of study entry) may be eligible after approval by the Principal Investigator. Lumbar puncture not required in asymptomatic patients. Prior history of Grade 3 or 4 sensory or motor neuropathy related to chemotherapeutic treatment, or persistent Grade 2 or greater active neuropathy. History of active neurologic disorders unrelated to chemotherapy (including familial neurologic diseases and acquired demyelinating disorders). Prior history of hypersensitivity reactions to vincristine or any of the other components of VSLI. Pregnant and/or lactating women; or fertile men or women not willing to use contraception.

Sites / Locations

  • Emory University
  • University of Chicago Medical Center
  • University of Texas M.D. Anderson Cancer Center

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

VSLI

Arm Description

Vincristine Sulfate Liposomes Injection (VSLI)

Outcomes

Primary Outcome Measures

MTD of VSLI
Subjects had to receive at least 1 course consisting of 4 weekly infusions of VSLI at the assigned drug dose with a minimum 2 weeks of observation after the last VSLI dose to be included in the evaluation of the MTD.

Secondary Outcome Measures

Full Information

First Posted
September 1, 2005
Last Updated
December 10, 2019
Sponsor
Acrotech Biopharma Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT00144963
Brief Title
Liposomal Vincristine Plus Dexamethasone in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Official Title
Phase I-II Study of Liposomal Vincristine (VSLI) and Dexamethasone in Relapsed or Refractory Acute Lymphoblastic Leukemia
Study Type
Interventional

2. Study Status

Record Verification Date
December 2019
Overall Recruitment Status
Completed
Study Start Date
July 2002 (undefined)
Primary Completion Date
August 2006 (Actual)
Study Completion Date
August 2006 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Acrotech Biopharma Inc.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to find the highest safe dose and to assess the anti-tumor effect of liposomal vincristine with dexamethasone in patients with relapsed or refractory acute lymphoblastic leukemia (ALL).
Detailed Description
OBJECTIVES: Determine the maximum tolerated dose (MTD) of liposomal vincristine given with dexamethasone in patients with relapsed or refractory acute lymphoblastic leukemia (ALL). Determine the efficacy of liposomal vincristine given with dexamethasone in these patients.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Lymphoblastic Leukemia

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
36 (Actual)

8. Arms, Groups, and Interventions

Arm Title
VSLI
Arm Type
Experimental
Arm Description
Vincristine Sulfate Liposomes Injection (VSLI)
Intervention Type
Drug
Intervention Name(s)
Vincristine Sulfate Liposomes Injection
Other Intervention Name(s)
Marqibo
Intervention Description
Study treatment consists of infusion of VSLI intravenously over 60 minutes on Day 1 and Days 8, 15 and 22 (+/- 2 days).
Intervention Type
Drug
Intervention Name(s)
Dexamethasone
Intervention Description
Study treatment consists of 40 mg dexamethasone, daily orally or intravenously, on Days 1-4 (+/- 2 days) and Days 11-14 (+/- 2 days).
Primary Outcome Measure Information:
Title
MTD of VSLI
Description
Subjects had to receive at least 1 course consisting of 4 weekly infusions of VSLI at the assigned drug dose with a minimum 2 weeks of observation after the last VSLI dose to be included in the evaluation of the MTD.
Time Frame
6 weeks

10. Eligibility

Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Previously treated, relapsed or refractory ALL (including lymphoblastic lymphoma and Burkitt's subtypes) with measurable disease. Performance status ≤3 (ECOG). All ages are eligible. Those aged 12 years or older may be counted towards the MTD in the Phase I portion of the trial. Pediatric patients are eligible, but must be treated at a dose level previously tested in an adult (one full course). Adequate liver function (bilirubin ≤2 x upper limit normal), and renal function (creatinine ≤2 x upper limit normal). Negative pregnancy test in females of childbearing potential. Patients with prior history of stem cell transplant are eligible if they meet all other eligibility requirements. Exclusion Criteria: Active serious infection not controlled by oral or intravenous antibiotics. Treatment with any investigational agents or chemotherapy agents in the last 21 days before study entry, unless full recovery from side effects has occurred or the patient has rapidly progressive disease judged to be life threatening by the Investigator. Concurrent treatment with other anti-cancer agents other than dexamethasone. Known CNS leukemia or lymphoma requiring intrathecal or craniospinal radiation therapy or with CNS neuropathy limiting evaluation of study drug. Patients with controlled CNS disease (no progression signs or symptoms at the time of study entry) may be eligible after approval by the Principal Investigator. Lumbar puncture not required in asymptomatic patients. Prior history of Grade 3 or 4 sensory or motor neuropathy related to chemotherapeutic treatment, or persistent Grade 2 or greater active neuropathy. History of active neurologic disorders unrelated to chemotherapy (including familial neurologic diseases and acquired demyelinating disorders). Prior history of hypersensitivity reactions to vincristine or any of the other components of VSLI. Pregnant and/or lactating women; or fertile men or women not willing to use contraception.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Deborah Thomas, MD
Organizational Affiliation
MD Anderson Cancer Center, Department of Hematology/Oncology
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Wendy Stock, MD
Organizational Affiliation
University of Chicago
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Leonard Heffner, MD
Organizational Affiliation
Emory University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Emory University
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30322
Country
United States
Facility Name
University of Chicago Medical Center
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60637
Country
United States
Facility Name
University of Texas M.D. Anderson Cancer Center
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Liposomal Vincristine Plus Dexamethasone in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

We'll reach out to this number within 24 hrs